Back to Peptides
RecoveryMedium Risk

Teduglutide

Also known as: Gattex, Revestive, GLP-2 analogue

Half-life:
~2 hours

Administration Routes

subcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

A GLP-2 analogue that promotes intestinal growth and repair. FDA-approved for short bowel syndrome; studied for IBD and gut restoration after intestinal damage.

Primary Research Areas

  • intestinal growth
  • gut repair
  • absorptive surface restoration
  • short bowel syndrome treatment

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Prescription OnlyFDA Approved

FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.

Effective: December 21, 2012View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Teduglutide

No active associated providers listed yet.